{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:36:11Z","timestamp":1778056571732,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00228-024-03672-y","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:54:28Z","timestamp":1710914068000},"page":"1039-1050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation"],"prefix":"10.1007","volume":"80","author":[{"given":"Paul","family":"Dobry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"McGrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amna","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"ASCEND-HIGHER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"3672_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB (2020) Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res 127:4\u201320","journal-title":"Circ Res"},{"key":"3672_CR2","doi-asserted-by":"crossref","unstructured":"Chung MK, Eckhardt LL, Chen LY et al (2020) Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the american heart association. Circulation 141(16):e750\u2013e772. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32148086\/","DOI":"10.1161\/CIR.0000000000000748"},{"key":"3672_CR3","unstructured":"Stierman B, Afful J, Carroll MD et al (2021) National Health and Nutrition Examination Survey 2017\u2013March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Natl Health Stat Report [Internet]. 2021(158). Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/106273"},{"key":"3672_CR4","unstructured":"Obesity and overweight [Internet]. World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 6 Mar 2023"},{"issue":"20","key":"3672_CR5","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","volume":"292","author":"TJ Wang","year":"2004","unstructured":"Wang TJ, Parise H, Levy D et al (2004) Obesity and the Risk of New-Onset Atrial Fibrillation. JAMA 292(20):2471\u20132477.\u00a0 Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/199858","journal-title":"JAMA"},{"key":"3672_CR6","doi-asserted-by":"crossref","unstructured":"Tsang TSM, Barnes ME, Miyasaka Y et al (2008) Editor\u2019s choice: obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 29(18):2227-2233. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18611964\/","DOI":"10.1093\/eurheartj\/ehn324"},{"issue":"4","key":"3672_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.amjcard.2010.10.018","volume":"107","author":"M Guglin","year":"2011","unstructured":"Guglin M, Maradia K, Chen R, Curtis AB (2011) Relation of Obesity to Recurrence Rate and Burden of Atrial Fibrillation. Am J Cardiol 107(4):579\u2013582","journal-title":"Am J Cardiol"},{"key":"3672_CR8","doi-asserted-by":"crossref","unstructured":"Thacker EL, McKnight B, Psaty BM et al (2013) Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. J Gen Intern Med 28(2):247\u2013253. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22972153\/","DOI":"10.1007\/s11606-012-2220-4"},{"key":"3672_CR9","doi-asserted-by":"crossref","unstructured":"Link MS, Giugliano RP, Ruff CT et al (2017) Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial. Circ Arrhythm Electrophysiol 10(1):e004267. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28077507\/","DOI":"10.1161\/CIRCEP.116.004267"},{"key":"3672_CR10","doi-asserted-by":"crossref","unstructured":"Steinberg BA, Hellkamp AS, Lokhnygina Y et al (2015) Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 36(5):288\u2013296. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25209598\/","DOI":"10.1093\/eurheartj\/ehu359"},{"issue":"31","key":"3672_CR11","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","volume":"34","author":"SM Al-Khatib","year":"2013","unstructured":"Al-Khatib SM, Thomas L, Wallentin L et al (2013) Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation results from the ARISTOTLE trial. Eur Heart J 34(31):2464\u20132471","journal-title":"Eur Heart J"},{"key":"3672_CR12","doi-asserted-by":"crossref","unstructured":"Navar AM, Kolkailah AA, Overton R et al (2022) Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc 11(22):e026723. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36346063\/","DOI":"10.1161\/JAHA.122.026723"},{"issue":"7","key":"3672_CR13","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1161\/STROKEAHA.120.029541","volume":"51","author":"A Mentias","year":"2020","unstructured":"Mentias A, Heller E, Sarrazin MV (2020) Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy. Stroke 51(7):2076\u20132086","journal-title":"Stroke"},{"issue":"22","key":"3672_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros e Silva PGM et al (2020) Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. New England J Med 383(22):2117\u20132126","journal-title":"New England J Med"},{"issue":"2","key":"3672_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ehjcvp\/pvy025","volume":"5","author":"CI Coleman","year":"2019","unstructured":"Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL (2019) Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA 2 DS 2 -VASc score of 1. Eur Heart J Cardiovasc Pharmacother 5(2):64\u201369","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"3672_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England J Med 365(10):883\u2013891. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1009638","journal-title":"New England J Med"},{"issue":"11","key":"3672_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England J Med 365(11):981\u2013992. Available from:\u00a0https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1107039","journal-title":"New England J Med"},{"issue":"6","key":"3672_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76(6):908\u2013916. Available from: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.lib.wayne.edu\/23488672\/","journal-title":"Br J Clin Pharmacol"},{"key":"3672_CR19","doi-asserted-by":"crossref","unstructured":"Mueck W, Lensing AW, Agnelli G et al (2011) Rivaroxaban population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):657\u2013686. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21895039\/","DOI":"10.2165\/11595320-000000000-00000"},{"issue":"6","key":"3672_CR20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308\u20131313","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3672_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10557-020-07126-2","volume":"35","author":"A Briasoulis","year":"2021","unstructured":"Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, Vaughan Sarrazin MS (2021) Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. Cardiovasc Drugs Ther 35(2):261\u2013272","journal-title":"Cardiovasc Drugs Ther"},{"issue":"20","key":"3672_CR22","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","volume":"139","author":"SH Hohnloser","year":"2019","unstructured":"Hohnloser SH, Fudim M, Alexander JH et al (2019) Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the Aristotle Trial. Circulation 139(20):2292\u20132300. Available from:\u00a0https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/CIRCULATIONAHA.118.037955","journal-title":"Circulation"},{"issue":"8","key":"3672_CR23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thrombosis Haemostasis 19(8):1874\u20131882. Available from:\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/jth.15358","journal-title":"J Thrombosis Haemostasis"},{"issue":"11","key":"3672_CR24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J Thrombosis Haemostasis 13(11):2119\u20132126. Available from: http:\/\/www.jthjournal.org\/article\/S1538783622086974\/fulltext","journal-title":"J Thrombosis Haemostasis"},{"issue":"2","key":"3672_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1060028018796604","volume":"53","author":"K Kido","year":"2018","unstructured":"Kido K, Ngorsuraches S (2018) Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.\u00a0https:\/\/doi.org\/10.1177\/1060028018796604. 53(2):165\u2013170. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018796604","journal-title":"Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation."},{"issue":"7","key":"3672_CR26","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","volume":"6","author":"M Kushnir","year":"2019","unstructured":"Kushnir M, Choi Y, Eisenberg R et al (2019) Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 6(7):e359\u2013e365","journal-title":"Lancet Haematol"},{"issue":"4","key":"3672_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1060028019886092","volume":"54","author":"IJ Perales","year":"2019","unstructured":"Perales IJ, San Agustin K, DeAngelo J, Campbell AM (2019) Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.\u00a0https:\/\/doi.org\/10.1177\/1060028019886092. 54(4):344\u2013350.\u00a0. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019886092?url_ver=Z39.88-2003&rfr_id=ori\/3Arid\/3Acrossref.org&rfr_dat=cr_pub++0pubmed","journal-title":"Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight."},{"key":"3672_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2019.02.001","volume":"212","author":"ED Peterson","year":"2019","unstructured":"Peterson ED, Ashton V, Chen YW et al (2019) Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 212:113\u2013119","journal-title":"Am Heart J"},{"key":"3672_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.015","author":"T Patil","year":"2023","unstructured":"Patil T, Lebrecht MA (2023) single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Available from: https:\/\/doi.org\/10.1016\/j.thromres.2020.04.015","journal-title":"Available from:"},{"key":"3672_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.amjcard.2020.03.048","volume":"126","author":"K Kido","year":"2020","unstructured":"Kido K, Shimizu M, Shiga T, Hashiguchi M (2020) Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation. Am J Cardiol 126:23\u201328. Available from: http:\/\/www.ajconline.org\/article\/S0002914920303374\/fulltext","journal-title":"Am J Cardiol"},{"key":"3672_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MJT.0000000000001403","volume":"28","author":"M Mhanna","year":"2021","unstructured":"Mhanna M, Beran A, Al-Abdouh A et al (2021) Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation A Systematic Review and Meta-analysis. Am J Ther 28:531\u2013539. Available from:\u00a0https:\/\/www.americantherapeutics.com","journal-title":"Am J Ther"},{"issue":"7","key":"3672_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/03007995.2020.1762554","volume":"36","author":"OS Costa","year":"2020","unstructured":"Costa OS, Beyer-Westendorf J, Ashton V et al (2020) Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin 36(7):1081\u20131088","journal-title":"Curr Med Res Opin"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03672-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:32:33Z","timestamp":1717731153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03672-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ascension St. John IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors met to discuss results and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}